PAQ Therapeutics
PAQ Therapeutics: A biotech leader in autophagy-based therapies for health restoration and disease cure.
Founded
2020PAQ Therapeutics: A biotech leader in autophagy-based therapies for health restoration and disease cure.
Founded with a mission to harness the power of autophagy for health restoration and disease cure, PAQ Therapeutics is a biotechnology company at the forefront of developing autophagy-based therapies. The company focuses on creating a new class of small molecule degradation therapies that extend beyond targeting proteins to eliminate disease-causing entities. By leveraging the body's natural cellular degradation mechanism, PAQ Therapeutics aims to offer innovative solutions for a range of diseases, positioning itself in the cutting-edge sector of biotech.
PAQ Therapeutics has attracted notable investors and industry leaders who support its pioneering approach. The company's achievements include advancing its proprietary platform driven by autophagosome-tethering compounds, which has shown promise in preclinical studies. With a global team dedicated to pushing the boundaries of medical science, PAQ Therapeutics is making significant strides in the biotech industry, potentially transforming therapeutic strategies and improving patient outcomes worldwide.
Companies similar to PAQ Therapeutics include Casma Therapeutics, Samsara Therapeutics, Capacity Bio and Kymera Therapeutics.
PAQ Therapeutics was founded in 2020.
PAQ Therapeutics' headquarters is located in Cambridge, MA, US.
PAQ Therapeutics' most recent funding round was for $30M (USD) in July 2021.
As of Jul 15, 2021, PAQ Therapeutics has disclosed funding of $30M (USD). Undisclosed round amounts are excluded.
PAQ Therapeutics has 6 employees as of Feb 4, 2024.
Kymera Therapeutics
kymeratx.com
